Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03720418
Recruitment Status : Recruiting
First Posted : October 25, 2018
Last Update Posted : August 30, 2019
Sponsor:
Collaborator:
Oxford BioMedica
Information provided by (Responsible Party):
Axovant Sciences Ltd.

Brief Summary:
This study consists of two parts. Part A will evaluate the safety and tolerability of multiple doses of OXB-102 (AXO-Lenti-PD) in patients with Parkinson's disease. Part B will assess the safety and efficacy of the selected dose of OXB-102 in patients with Parkinson's disease.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: OXB-102 Other: Imitation Surgical Procedure (ISP) Phase 1 Phase 2

Detailed Description:
This study consists of two parts. Part A is an open-label dose-escalation phase in which patients are enrolled in cohorts and will receive one of approximately three escalating doses of OXB-102 (AXO-Lenti-PD). Part B is a randomized, double-blind phase in which patients will be randomized to either an active group receiving the selected dose from Part A, or to a control group receiving an imitation surgical procedure (ISP).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Study Part A open-label and Study Part B randomized, double-blind
Primary Purpose: Treatment
Official Title: A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease
Actual Study Start Date : October 17, 2018
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : December 2031

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: OXB-102 Dose Level 1
OXB-102 Dose Level 1 Single Administration (Part A: open-label)
Drug: OXB-102
Neurosurgical delivery of OXB-102 (gene therapy) to the striatum
Other Name: AXO-Lenti-PD

Experimental: OXB-102 Dose Level 2
OXB-102 Dose Level 2 Single Administration (Part A: open-label)
Drug: OXB-102
Neurosurgical delivery of OXB-102 (gene therapy) to the striatum
Other Name: AXO-Lenti-PD

Experimental: OXB-102 Dose Level 3
OXB-102 Dose Level 3 Single Administration (Part A: open-label)
Drug: OXB-102
Neurosurgical delivery of OXB-102 (gene therapy) to the striatum
Other Name: AXO-Lenti-PD

Experimental: OXB-102 Selected Dose
Selected Dose of OXB-102 Single Administration (Part B: double-blind)
Drug: OXB-102
Neurosurgical delivery of OXB-102 (gene therapy) to the striatum
Other Name: AXO-Lenti-PD

Sham Comparator: Imitation Surgical Procedure
General anesthesia with bilateral skin incisions (Part B: double-blind)
Other: Imitation Surgical Procedure (ISP)
Patients randomized to the control group in Part B will receive an ISP




Primary Outcome Measures :
  1. Safety of OXB-102-01 as measured by incidence of treatment emergent adverse events and serious adverse events [ Time Frame: 3 months timepoint ]
    Treatment emergent adverse events and serious adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for severity

  2. Safety of OXB-102-01 as measured by changes in clinical laboratory analysis [ Time Frame: 3 months timepoint ]
    Number of clinically significant changes in clinical laboratory analysis

  3. Safety of OXB-102-01 as measured by changes in vital signs [ Time Frame: 3 months timepoint ]
    Number of clinically significant changes in vital signs

  4. Safety of OXB-102-01 as measured by changes in brain MRI findings [ Time Frame: 3 months timepoint ]
    Number of clinically significant changes in brain MRI findings

  5. Safety of OXB-102-01 as measured by changes in physical examination [ Time Frame: 3 months timepoint ]
    Number of clinically significant changes in physical examination


Secondary Outcome Measures :
  1. The change in Unified Parkinson's Disease Rating Scale (UPDRS) scores compared to baseline in defined "OFF" and "ON" medication states [ Time Frame: 6 months timepoint ]
  2. The change in motor fluctuations compared to baseline as assessed by patient diaries [ Time Frame: 6 months timepoint ]
  3. The change in dyskinesia rating scale from baseline [ Time Frame: 6 months timepoint ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   48 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosed with bilateral idiopathic PD for at least 5 years (at the time of surgery)
  2. Males/females between 48 and 70 years at the time of surgery
  3. Presence of motor fluctuations and/or dyskinetic movement
  4. Candidate for surgical intervention
  5. Hoehn and Yahr (H&Y) Stage 3 or 4 in the "OFF" medication state
  6. Stable dosing of PD medication, including L-DOPA, for four weeks prior to screening

Exclusion Criteria:

  1. History of psychosis or current treatment with dopamine blocking agents and prior regular exposure to antipsychotic agents
  2. History of stereotactic or other surgery for the treatment of PD, including Deep Brain Stimulation (DBS)
  3. Participation in a prior cell or gene transfer therapy study
  4. Contraindications to use of anaesthesia
  5. Current or anticipated treatment with anticoagulant therapy or the use of anticoagulation therapy that cannot be temporarily stopped around the time of surgery
  6. Diagnosis of multiple system atrophy
  7. Abnormal MRI findings such as mega cisterna, septum pellucidum, signs of severe cortical or subcortical atrophy, brain tumours, vascular diseases, trauma or arteriovenous malformations
  8. Presence of dementia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03720418


Contacts
Layout table for location contacts
Contact: Travis B Lewis, MD, PhD 1-646-593-8403 travis.lewis@axovant.com
Contact: Rizalyn Golnar 1 -646-495-5312 Rizalyn.Golnar@axovant.com

Locations
Layout table for location information
France
Service de Neurochirurgie, Hôpital Henri Mondor Not yet recruiting
Créteil, France, 94010
United Kingdom
University of Cambridge, Centre for Brain Repair Recruiting
Cambridge, Cambridgeshire, United Kingdom, CB2 0PY,
The National Hospital for Neurology and Neurosurgery Recruiting
London, United Kingdom, WC1N 3BG
Sponsors and Collaborators
Axovant Sciences Ltd.
Oxford BioMedica
Investigators
Layout table for investigator information
Study Director: Travis B Lewis, MD, PhD Axovant Sciences

Layout table for additonal information
Responsible Party: Axovant Sciences Ltd.
ClinicalTrials.gov Identifier: NCT03720418     History of Changes
Other Study ID Numbers: OXB-102-01
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: August 30, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Axovant Sciences Ltd.:
Parkinson's disease
Gene therapy
OXB-102
AXO-Lenti-PD
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases